Erythropoietin levels are not independently associated with malaria-attributable severe disease in Mozambican children. by Díez-Padrisa, Núria et al.
Dez-Padrisa, Nria; Aguilar, Ruth; Machevo, Sonia; Morais, Luis;
Nhampossa, Tacilta; OCallaghan-Gordo, Cristina; Nhalungo, Delino;
Menndez, Clara; Roca, Anna; Alonso, Pedro L; Bassat, Quique (2011)
Erythropoietin Levels Are Not Independently Associated with Malaria-
Attributable Severe Disease in Mozambican Children. PLoS ONE, 6
(8). e24090-e24090. DOI: https://doi.org/10.1371/journal.pone.0024090
Downloaded from: http://researchonline.lshtm.ac.uk/4650298/
DOI: 10.1371/journal.pone.0024090
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Erythropoietin Levels Are Not Independently Associated
with Malaria-Attributable Severe Disease in Mozambican
Children
Nu´ria Dı´ez-Padrisa1,2, Ruth Aguilar1,3, Sonia Machevo2,4, Luis Morais2, Tacilta Nhampossa2,5, Cristina
O’Callaghan-Gordo1,2, Delino Nhalungo2, Clara Mene´ndez1,2, Anna Roca1,2, Pedro L. Alonso1,2, Quique
Bassat1,2,3*
1Centre de Recerca en Salut Internacional de Barcelona, Hospital Clı´nic, Universitat de Barcelona, Barcelona, Spain, 2Centro de Investigac¸ao˜ em Sau´de da Manhic¸a,
Manhic¸a, Mozambique, 3CIBER de Epidemiologı´a y Salud Pu´blica (CIBERESP), Barcelona, Spain, 4 Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo,
Mozambique, 5 Instituto Nacional de Sau´de, Ministerio de Sau´de, Maputo, Mozambique
Abstract
Background: Severe malaria is difficult to differentiate from other forms of malaria or other infections with similar
symptoms. Any parameter associated to malaria-attributable severe disease could help to improve severe malaria diagnosis.
Methodology: This study assessed the relation between erythropoietin (EPO) and malaria-attributable severe disease in an
area of Mozambique with moderate malaria transmission. 211 children ,5 years, recruited at Manhic¸a District Hospital or in
the surrounding villages, were included in one of the following groups: severe malaria (SM, n = 44), hospital malaria without
severity (HM, n= 49), uncomplicated malaria (UM, n = 47), invasive bacterial infection without malaria parasites (IBI, n = 39)
and healthy community controls (C, n = 32). Malaria was diagnosed by microscopy and IBI by blood/cerebrospinal fluid
culture.
Principal Findings: Mean EPO concentration in the control group was 20.95 U/l (SD= 2.96 U/l). Values in this group were
lower when compared to each of the clinical groups (p = 0.026 C versus UM, p,0.001 C vs HM, p,0.001 C vs SM and
p,0.001 C vs IBI). In the 3 malaria groups, values increased with severity [mean= 40.82 U/l (SD = 4.07 U/l), 125.91 U/l
(SD = 4.99U/l) and 320.87 U/l (SD = 5.91U/l) for UM, HM and SM, respectively, p,0.001]. The IBI group [mean= 101.75 U/l
(SD = 4.12 U/l)] presented lower values than the SM one (p = 0.002). In spite of the differences, values overlapped between
study groups and EPO levels were only associated to hemoglobin. Hemoglobin means of the clinical groups were 93.98 g/dl
(SD = 14.77 g/dl) for UM, 75.96 g/dl (SD = 16.48 g/dl) for HM, 64.34 g/dl (SD= 22.99 g/dl) for SM and 75.67 g/dl
(SD = 16.58 g/dl) for IBI.
Conclusions: Although EPO levels increase according to malaria severity and are higher in severe malaria than in
bacteremia, the utility of EPO to distinguish malaria-attributable severe disease is limited due to the overlap of values
between the study groups and the main role of hemoglobin in the expression of EPO.
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Introduction
An optimal management of malaria needs a correct diagnosis
and a good assessment of severity. Presence of Plasmodium in blood
can easily be determined by microscopy or rapid diagnostic tests
(RDTs), but even when Plasmodium is observed, attribution of
symptomatology to malaria is not straightforward. In areas that
are hyper- or holo-endemic for malaria, children are exposed to
repeated infective bites during infancy and early childhood,
progressively acquiring immunity against the disease and devel-
oping clinical tolerance to malaria parasites [1]. Thus, the
detection of parasites in the blood of sick patients is not a
definitive proof of their association to the clinical symptoms.
Furthermore, clinical signs of malaria in children are highly
unspecific and often overlap with those of other infections such as
pneumonia, bacteremia or meningitis [1–5], all major causes of
morbidity and death among young children in developing
countries [6]. In such a context, severe malaria is difficult to
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differentiate from other infections. Any parameter associated to
malaria-attributable severe disease could help to improve severe
malaria diagnosis [7].
Additionally, the broad diversity of pathophysiological path-
ways, leading to the different syndromic presentations associated
to severe malaria, further hinders diagnosis. Severe malaria in
African children encompasses at least three main clinical
syndromes that can occur alone or in combination: severe malarial
anemia, cerebral malaria and respiratory distress (often secondary
to metabolic acidosis [8]). Acidosis, predominantly due to lactic
acid accumulation, has emerged as a central feature of severe
malaria [9]. Malarial acidosis is multifactorial [10], but results
mostly from increased host anaerobic glycolysis due to a mismatch
between tissue oxygen supply and requirement. Reduced tissue
oxygenation is central in malaria pathophysiology [11,12].
One of the mechanisms suggested to be causing tissue hypoxia
in malaria is severe anemia, a frequent clinical syndrome
secondary to hemolysis and suppression of erythropoiesis
[13,14]. Acute malaria hemolysis is characterized by increased
levels of unconjugated bilirubin and lactate dehydrogenase (LDH).
With the destruction of red blood cells, hemoglobin (Hb) and LDH
are released into the circulation. Liberated Hb is converted into
unconjugated bilirubin in the reticuloendothelial cells of the spleen
and transported to the liver, where it is conjugated to glucoronic
acid. However, when hemolysis is also extravascular, plasmatic
levels of unconjugated bilirubin increase because hepatocytes
cannot process the excess bilirubin [15]. The other two
mechanisms suggested to be causing tissue hypoxia in malaria
are obstruction of tissular blood flow, due to the adhesion of
parasitized and poorly deformable non-parasitized red blood cells
to endothelial walls of small vessels [16–18], and inhibition of
mitochondrial function by cytokines and nitric oxide [19].
Erythropoietin (EPO), a glycoprotein hormone principally
produced by the kidney’s peritubular capillary endothelial cells in
response to hypoxia, is crucial for sustained proliferation and
differentiation of erythroid cells [20]. Regulation of EPO is believed
to rely on a feed-back mechanism measuring blood oxygenation
through hypoxia inducible transcription factors [21]. In addition,
EPO is bound by circulating red blood cells; low circulating
numbers lead to a relatively high level of unbound EPO which
stimulates their production in the bone marrow [22]. Novel
pathways involving EPO indicate that the increased presence of
this molecule during periods of oxidative stress may result in cellular
mechanisms designed to protect from damaging reactive oxygen
species [23–25]. Several studies have described high levels of EPO
in African children with malaria [26–30], suggesting that EPO
might be a good indicator of malaria-attributable disease.
Assuming that hypoxia-related acidosis is the cardinal sign of
severe malaria and that EPO is the key molecule in the adaptation
to hypoxia; we hypothesized that EPO levels could be related to
malaria-attributable severe disease among children with different
degrees of malaria severity and children with no-malarial causes of
severe disease (bacteremia), in an area of Mozambique with
moderate malaria transmission.
Methods
Study area and population
This study was conducted at the Centro de Investigac¸a˜o em Sau´de da
Manhic¸a (CISM) and the Manhic¸a District Hospital (MDH), the
referral health facility for Manhic¸a District, a rural malaria-
endemic area of Southern Mozambique.
Since 1996, CISM has been running a continuous Demograph-
ic Surveillance System (DSS) and a morbidity surveillance
platform at the MDH. The DSS covers 500 km2 and approxi-
mately 80,000 inhabitants (18% children ,5 years) [31]. Under-
five mortality rate in the area was 139/1,000 in 2005 [31].
Malaria transmission, perennial but with substantial seasonality,
is mainly due to P. falciparum [32]. In 2003–2005, malaria
accounted for 30.5% of all pediatric outpatient visits [32] and 49%
of all pediatric admissions [33]. Almost 19% of all in-hospital
pediatric deaths were due to malaria [33]. According to WHO
criteria, 13.2% of admissions had severe malaria, being prostration
(55.0%), respiratory distress (41.1%) and severe anemia (17.3%)
the 3 most prevalent clinical presentations [33].
In Manhic¸a, P. falciparum and anemia show a considerable
overlap in the spatial and temporal distribution patterns. In a
community cross-sectional survey among healthy children, the
prevalence of anemia at the end of the rainy season was twice as
high than at the end of the dry season (34.4% versus 17.9%),
suggesting that malaria is an important contributor to anemia
[34]. Additionally, a negative correlation between asexual P.
falciparum density and packed cell volume was found [34]. Data
collected in 2003–2005 confirmed this relation, showing an
anemia prevalence of 47% among outpatient children ,5 years,
with 68.4% of the malaria cases being anemic [32].
Between 2001 and 2006, community-acquired bacteremia
accounted for 8% of all pediatric admissions and 21% of all in-
hospital deaths [35]. In 2006, acute bacterial meningitis was
suspected in 18% of all pediatric admissions and confirmed in 7%
of these cases, 24% of which died [36]. Severe malnutrition
prevalence in children,5 years old admitted to MDH was 10% in
2001–2003 [37]. HIV prevalence among pregnant women
attending the antenatal clinic was 23.6% in 2004 [38], mother-
to-child transmission occurred in 12.4% of the births and HIV
prevalence among the newborns was 3% [39].
Study design
Children included in this analysis were recruited as part of a
larger study designed to explore the use of certain cytokines/other
proteins to differentiate malaria, bacterial and viral infections
among children ,5 years old seen at MDH. Recruitment of the
larger study went from September 2006 to May 2009 and
included, among other patients, children with different degrees of
malaria severity or invasive bacterial infection. Data presented
here belong to those children from the larger study fulfilling the
group definitions of the present analysis and with plasma samples
available to perform EPO measurements. Written informed
consent was obtained from all participant parents/legal guardians
involved in the study. The study was approved by the
Mozambican National Bioethics Committee and Institutional
Review Board of the Hospital Clı´nic de Barcelona.
Children included in this analysis were classified into five
groups: severe malaria (SM), hospital malaria (HM), uncompli-
cated malaria (UM), invasive bacterial infection (IBI) and healthy
control (C). SM group was further stratified in severe malarial
anemia (SMA), cerebral malaria (CM) and mixed severe malaria
(MSM) subgroups. We used the HM group to describe an
intermediate severity group in malaria, including those children
judged to need hospitalization but without the criteria needed to
fulfill the severe malaria case definition. This non-standard
classification, also used in previous malaria vaccine trials [40],
may help classifying malaria cases in a gradient of increasing
severity. Children from the clinical groups were recruited at
MDH. For the control group, healthy children from the DSS area
were randomly selected maintaining the same pattern of age in the
clinical groups (40% children ,1 year, 30% children 1 to ,2
years and 30% children 2 to ,5 years).
EPO and Malaria-Attributable Severe Disease
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Standardized questionnaires with demographic and clinical data
were completed for recruited children together with the following
samples: i) finger prick blood smears for malaria microscopy; ii) 1–
3 ml of venous blood for bacterial culture; iii) 1.5 ml of venous
blood in EDTA for full blood count, EPO, bilirubin and LDH
measurements. Blood culture was not performed for the control
group. Cerebrospinal fluid (CSF) was only collected from
hospitalized children with suspicion of meningitis. Children in
the inpatient groups residing in the DSS area were offered
voluntary HIV counseling and testing. Additional written
informed consent and finger prick were needed for this purpose.
Study groups
Severe malaria (SM) was defined as the presence of fever
(axillary temperature $37.5uC) or reported history of fever in the
preceding 24 hours in children admitted with P. falciparum in blood
($500 asexual parasites/ml), a negative blood and CSF culture (if
available) and, at least, one of the following criteria: severe anemia
(hematocrit ,15% or Hb ,5g/dl), deep coma (Blantyre coma
score #2), prostration (inability to sit unaided or look for mother’s
breast/feed in children who cannot yet sit), hypoglycemia
(,2.2 mmol/l), repeated convulsions ($2 reported episodes in
the 24 hours prior to admission) or respiratory distress (deep
breathing or indrawing). Among SM group, children with only
severe anemia were classified in the severe malarial anemia (SMA)
subgroup and those with only neurological impairment including
prostration, convulsions or/and coma in the cerebral malaria
(CM) one. Finally, mixed severe malaria (MSM) subgroup
included those SM cases with SMA or/and CM accompanied
with any other criteria of SM and those SM cases with
hypoglycemia or/and respiratory distress.
Hospital malaria (HM) was defined as the presence of fever or
history of fever in the preceding 24 hours in children admitted
with P. falciparum in blood ($500 asexual parasites/ml), a negative
blood and CSF culture (if available) and not fulfilling inclusion
criteria for severe malaria.
Uncomplicated malaria (UM) was defined as the presence of fever
or history of fever in the preceding 24 hours, P. falciparum in blood
($500 asexual parasites/ml) and a negative blood culture in children
seen as outpatients with no clinical criteria for hospital admission.
Invasive bacterial infection (IBI) was defined in children
admitted with respiratory distress (chest indrawing and/or deep
breathing) as the presence of bacteria isolated from blood and/or
CSF and no P. falciparum in blood. Potential contaminants
(Staphylococcus epidermidis, gram-positive Bacillus and, only in blood,
Streptococcus viridans) were not included in this group.
Controls (C) included healthy children from the community with
no history of fever or detectable fever at recruitment, no report of
having received medical assistance/treatment during the last 30 days,
no signs or symptoms of illness and no P. falciparum parasites in blood.
Laboratory methods
P. falciparum parasites were detected by microscope observation
of thick and thin Giemsa-stained blood films as described
elsewhere [32]. Blood cultures were performed by incubating 1–
3 ml of blood during 4 days using an automated system
(BACTECH 9050, Becton-Dickinson, Franklin Lake, NJ, USA).
Positive blood cultures were examined following standard
procedures [37,41]. CSF were cultured using conventional
methods, bacterial isolates were identified by colony morphologic
analysis and growth requirements [36].
Full blood counts were performed using a Sysmex KX21
hematology analyzer (Sysmex Long Grove, IL, USA). Plasma
was obtained by blood centrifugation (5 minutes, 1500 rpm).
Plasma LDH and total-bilirubin (conjugated plus unconjugated)
were measured using a Vitros DT60 II biochemical analyser
(Orthoclinical Diagnostics, Rochester, NY, USA). Remaining
plasma was stored at 220uC and sent to the Hospital Clı´nic de
Barcelona, where EPO quantification was performed using
Quantikine human Erythropoietin (R&D Systems, Minneapolis, MN,
USA) immunoanalysis with a limit of detection of 0.6 U/ml.
HIV testing was done using two RDT: Determine (Abbott
Laboratories, North Chicago, IL, USA) and Unigold (Trinity
Biotech, Bray, Ireland). For children ,18 months positive by both
RDT and for those cases of discordant results between RDT, HIV-1
infection was confirmed using antigen DNA-PCR Roche HIV-1
DNA test (Roche Molecular Systems, Branchburg, NJ, USA).
Data management and statistical analysis
Data were double entered using Fox Pro version 2.6 (Microsoft
Corporation, Redmond, WA, USA) and discrepancies between
two entries were resolved referring to the original forms. Statistical
analyses were performed using STATA version 11 (Stata
Corporation, College Station, TX, USA).
Proportions were compared using Chi-square test. EPO and
bilirubin values were logarithmically transformed to perform the
analysis. In the case of malaria groups, test for trend was used to
assess lineal increase of different parameters with severity.
ANOVA test was performed to evaluate differences among
distributions of EPO, hemoglobin, bilirubin and LDH levels
between the study groups. Linear regression models were
estimated to evaluate the difference of EPO levels adjusted by
age, sex, malnutrition, hemoglobin and days of fever prior to visit/
admission. Univariate linear regression was used to explore the
relation between EPO/bilirubin/LDH and Hb. P-values #0.05
were considered significant.
Results
Study groups profile
This analysis is based on 211 children ,5 years recruited
between September 2006 and May 2009, 132 of which were
admitted to hospital. Distribution of the children according to
study groups was: SM (n= 44), HM (n= 49), UM (n= 47), IBI
(n = 39) and C (n = 32). Children in the SM group presented at
least one of the following criteria: respiratory distress (n = 29),
severe anemia (n = 16), prostration (n = 14), convulsions (n = 9),
deep coma (n = 2) and hypoglycemia (n = 1). Among these
children, 8 corresponded to the SMA subgroup, 6 to the CM
and 30 to the MSM. The following bacteria were isolated in the
IBI group: Streptococcus pneumoniae (n = 22), Haemophilus influenzae B
(n = 6), Escherichia coli (n = 4) Staphylococcus aureus (n = 3), Salmonella
spp (n= 2), Streptococus spp (n = 1) and Klebsiella pneumoniae (n = 1).
No bacterial co-infection was found.
Nine of the 124 admitted children with outcome data died in-
hospital. All fatalities occurred in the IBI group, which had an
associated case fatality rate of 28% (9/32). Severe anemia was
more prevalent in the SM group when compared to the other
groups (36% versus 5%, 0% and 0% in the IBI, HM and UM,
respectively). Demographic and clinical features of the study
groups are shown in Table 1.
EPO levels in the study groups
Although values overlapped between study groups, differences
in the distribution of EPO levels were observed (p,0.001)
(Figure 1). Mean EPO concentration in the control group was
20.95 U/l (SD=2.96 U/l). Values in this group were lower when
compared to each of the clinical groups (p = 0.026 C vs UM,
p,0.001 C vs HM, p,0.001 C vs SM and p,0.001 C vs IBI).
EPO and Malaria-Attributable Severe Disease
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EPO levels in the 3 malaria groups increased with increasing
severity (n = 47, 49 and 44, p,0.001), with mean values of
40.82 U/l (SD=4.07 U/l) for UM, 125.91 U/l (SD=4.99 U/l)
for HM and 320.87 U/l (SD=5.91 U/l) for SM. For the IBI
group, mean EPO concentration was 101.75 U/l (SD=4.12 U/l).
Values in this group were lower than those in the SM group
(n = 39 and n= 44, p = 0.002).
When stratifying SM group in SMA, CM and MSM, differences
on EPO levels were observed among the subgroups (n = 8, n= 6
and n= 30, p,0.001) (Figure 2), with mean values of 1439.38 U/l
(SD=1.79 U/l) for SMA, 29.45 U/l (SD=2.89 U/l) for CM and
346.69 U/l (SD=5 U/l) for MSM.
Association of EPO levels with descriptive parameters in
the clinical groups
The association of EPO levels with demographic and clinical
parameters in the clinical groups is illustrated in Table 2. SM
group was used as the baseline when comparing study groups. In
the crude analysis, EPO levels appeared associated to the study
group (n= 179, p,0.004 SM vs HM, p,0.001 SM vs UM and
p= 0.001 SM vs IBI) and the Hb concentration (n= 173,
p,0.001). An inverse relationship was observed between EPO
and Hb [b(SE) = 0.93 (0.003), p,0.001], being Hb levels lower in
the groups with higher levels of EPO. Hb levels decreased in the
malaria groups (n = 42, 48 and 44, p,0.001), with mean values of
93.98 g/dl (SD=14.77 g/dl) for UM, 75.96 g/dl (SD=16.48 g/
dl) for HM and 64.34 g/dl (SD=22.99 g/dl) for SM. For the IBI
group, mean Hb concentration was 75.67 g/dl (SD=16.58 g/dl)
and higher than in the SM group (n = 39 and 44, p = 0.013)
(Table 1).
After adjusting EPO levels by age, sex, malnutrition,
hemoglobin and days of fever prior to visit/admission in the
multivariate analysis, EPO only remained associated to Hb
concentration (n = 149, p,0.001). Identical results were observed
Table 1. Demographic and clinical features of the study groups.
Variables Group
a p-value
C
(n = 32)
UM
(n = 47)
HM
(n = 49)
SM
(n = 44)
IBI
(n = 39)
HM,
UM & SMb SM & IBI
Age, months (n = 211) 17 (6–26) 31 (19–42) 22 (16–33) 25 (14–40) 10 (4–16) 0.211 ,0.001
Sex (n = 211)
Male 22 (69) 30 (64) 25 (51) 27 (61) 24 (62) 0.792 0.987
Female 10 (31) 17 (36) 24 (49) 17 (39) 15 (38)
Days of fever prior to visit/admission (n = 162)
#3 NAc 44 (94) 37 (86) 30 (91) 32 (82) 0.605 0.279
.3 NA 3 (6) 6 (14) 3 (9) 7 (18)
Severe malnutritiond (n = 159)
No NA 46 (100) 39 (93) 33 (89) 26 (76) 0.032 0.153
Yes NA 0 (0) 3 (7) 4 (11) 8 (24)
Hemoglogin, g/dl (n = 173) NA 93.98 (14.77) 75.96 (16.48) 64.34 (22.99) 75.67 (16.58) ,0.001 0.013
Severe anemiae (n = 179)
No NA 47 (100) 49 (100) 28 (64) 37 (95) ,0.001 0.001
Yes NA 0 (0) 0 (0) 16 (36) 2 (5)
Lactic acidosisf (n = 67)
No NA NA NA 18 (64) 29 (74) NA 0.374
Yes NA NA NA 10 (36) 10 (26)
Oxigen saturationg (n = 67)
$94% NA NA NA 21 (75) 20 (49)
90-,94% NA NA NA 3 (11) 8 (19) NA 0.145
,90% NA NA NA 4 (14) 11 (32)
HIV (n = 43)
Negative NA NA NA 15 (83) 10 (40) NA 0.004
Positive NA NA NA 3 (17) 15 (60)
Outcome (n = 124)
Alive NA NA 48 (100) 44 (100) 23 (72) NA ,0.001
Death NA NA 0 (0) 0 (0) 9 (28)
NOTE. Median and inter-quartile range (IQR) for age. Mean and standard deviation (SD) for hemoglobin. Other data are n (%) of patients.
aC: control, UM: uncomplicated malaria, HM: hospital malaria, SM: severe malaria, IBI: invasive bacterial infection.
bTest for linear trend.
cNA: Not applicable.
dWeight for age z-score ,-3 from U.S. reference population.
eHematocrit ,15% or hemoglobin ,5 g/dl.
fPlasma lactate .5 mmol/l.
doi:10.1371/journal.pone.0024090.t001
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when repeating the analysis stratifying SM in SMA, CM and
MSM subgroups (data not shown). When evaluating the role of
the clinical group in the association between EPO and Hb no
interaction was observed (data not shown).
Hemolysis markers (bilirubin and LDH) and their relation
with Hb in the SM and IBI groups
As shown in Figure 3A, bilirubin levels in the SM group were
higher than in the IBI one (n= 28 and 31, p,0.001). Mean values
for bilirubin were 21.62 mmol/l (SD=1.87 mmol/l) for the SM
group and 9.99 mmol/l (SD=2.4 mmol/l) for the IBI group. When
exploring the relation between bilirrubin and Hb, no correlation
was observed between the two variables either in the SM and the
IBI groups (data not shown).
Although levels of LDH were higher in the SM group compared
to the IBI group, values between the two groups overlapped
(n= 27 and 35, p = 0.182) (Figure 3B). Mean LDH concentrations
were 1564.96 U/l (SD=800.59 U/l) in the SM group and
1296.83 U/l (SD=756.90 U/l) in the IBI group. When exploring
the relation between LDH and Hb, a negative correlation of
values between the two variables was observed in the SM group
[b(SE) =214.75 (7.06), p = 0.047].
Figure 1. Distribution of EPO levels (U/l) in the study groups.
doi:10.1371/journal.pone.0024090.g001
Figure 2. Distribution of EPO levels (U/l) in the SM subgroups.
doi:10.1371/journal.pone.0024090.g002
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Discussion
In the present study, we have assessed the relation between EPO
and malaria-attributable severe disease among children with
malaria (uncomplicated, hospitalized without severity and severe)
or severe infection (severe malaria and bacteremia). The main
findings are that in our setting, despite EPO levels increase
according to malaria severity and the SM group presents higher
levels of EPO than the IBI group, the utility of EPO to distinguish
malaria-attributable severe disease is limited due to the overlap of
values between the study groups and the main role of hemoglobin
in the expression of EPO.
According to the results, SM cases presented the highest levels of
EPO among the study groups and EPO levels increased
progressively with malaria severity. Despite being IBI the group
with the most severe cases in the study (as reflected by its higher case
fatality rate), EPO levels were higher in the SM group when
compared to the IBI one. These observations may apparently
suggest that EPO could be useful to distinguish malaria-attributable
severe disease. However, this conclusion cannot be assumed from
this study as the results show that the differences observed on EPO
levels depend only on the Hb levels and not on the group (even
when considering the different forms of SM separately). In
consequence, the visible pattern of EPO distribution among the
study groups should vary according to the degree of anemia. This
observation contrasts with data fromKenya, where EPO levels were
found 3.5 times higher in children with mild malarial anemia than
in those without malaria and mild to moderate anemia [27]. A
possible explanation to the differences between the two studies could
be that the high prevalence (36%) of severe anemia among SM cases
in the present study is diluting the effect of other factors linked to the
clinical condition in modulating the relation between EPO and Hb.
Additionally and irrespectively of the role of Hb in the distribution
of EPO, the current overlap of EPO values between the study
groups hinders its utility in SM diagnosis.
Although the previous results lack of practicality in terms of
improving clinical diagnosis of SM, they can however contribute
to understand the pathophysiological processes underlying the
expression of EPO. Despite EPO being produced in response to
hypoxia and different factors (not only hemolysis) may trigger its
expression [24], in our setting hypoxia due to anemia seems to
play a principal role as the only factor associated to EPO was Hb.
In agreement with that, the highest levels of bilirubin and LDH
(both indicators of hemolysis) concentrated in the SM group,
Table 2. Association of EPO levels with descriptive parameters in the clinical groups.
Variables Crude analysis Adjusted analysis
a (n = 149)
Proportional
difference 95% CI p-value
Proportional
difference 95% CI p-value
Group (n = 179)
SM 1 1
HM 0.39 0.21–0.74 0.004 0.92 0.57–1.49 0.730
UM 0.13 0.07–0.24 ,0.001 1.18 0.68–2.03 0.550
IBI 0.32 0.16–0.62 0.001 0.68 0.39–1.18 0.169
Age (n = 179) b 0.99 0.97–1 0.151 1 0.99–1.01 0.890
Sex (n = 179)
Male 1 1
Female 0.99 0.59–1.66 0.972 1.17 0.83–1.65 0.355
Days of fever prior to
visit/admission (n = 162) b
1.22 1.03–1.44 0.020 1.02 0.91–1.13 0.777
Hemoglobin (n = 173) b 0.93 0.93–0.94 ,0.001 0.93 0.92–0.94 ,0.001
Severe malnutrition (n = 159)
No 1 1
Yes 2.08 0.83–5.20 0.115 1.08 0.58–2 0.815
Lactic acidosis (n = 67)
No 1 NA c
Yes 0.87 0.37–2.07 0.754 NA NA NA
Oxygen saturation (n = 67)
$94% 1 NA
90-,94% 2.12 0.71–6.31 0.173 NA NA NA
,90% 1.17 0.44–3.09 0.743 NA NA NA
HIV (n = 43)
No 1 NA
Yes 1.70 0.6–4.83 0.307 NA NA NA
Malaria parasites (n = 179) b 1 0.99–1 0.217 NA NA NA
aThe analysis was done adjusting by age, sex, malnutrition, hemoglobin and days of fever prior to visit/admission.
bProportional increment per unit. Age in months, hemoglobin in g/dl and malaria parasites in asexual parasites/ml.
cNA: Not applicable.
doi:10.1371/journal.pone.0024090.t002
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coinciding with the highest ratios of severe anemia and EPO levels
among the study children. Furthermore, when comparing EPO
levels among SMA, CM and MSM, highest values of EPO were
found among children with only severe anemia. Also an age-
dependent EPO response to anemia has been described in
malaria-endemic areas [42,43], coinciding with the distribution
of SMA in younger ages and CM in older ages. However, we
could not detect this association in our sample, which may be
related to the fact that in Manhic¸a CM cases also occur among
infants and younger children [33]. In our study, 2 out of 6 children
with CM were #14 months old.
Besides the hypoxia due to anemia, it has been described that in
severe malaria the oxygen delivery to tissues is poorer than in
sepsis as indicated by the acidosis and the much higher ratios of
serum lactate/pyruvate [11,12]. However, no differences in
acidosis and oxygen saturation were detected when comparing
SM and IBI groups. This can contribute to explain why no
association between EPO levels and study groups was found in our
sample. Additionally, the duration of the infection has been
associated to the clinical profile of malaria [44], suggesting that
this parameter could be related to EPO. No association between
duration of the infection (as characterized by number of days of
fever prior to visit/admission) and EPO was detected in our
sample, but results may be biased as 88% (143/162) of the cases
with data of fever duration prior to visit/admission presented the
same pattern (#3 days of fever prior to visit/admission). Why we
only observed the effect of Hb in the expression of EPO levels is
unclear. A possible explanation is that the strong influence of
anemia in our sample may be hiding the contribution of other
factors, besides Hb, to the expression of EPO.
Figure 3. Distribution of bilirubin (mmol/l) and LDH (U/l) in the SM and IBI groups.
doi:10.1371/journal.pone.0024090.g003
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Leaving aside the mechanisms that could explain the distribu-
tion of EPO levels in this study, the results indicate that the utility
of EPO to distinguish malaria-attributable severe disease is limited,
at least, in settings with high prevalence of anemia among ill
children. From these results, we cannot state that the suspicion of
SM on the basis of elevated levels of EPO could be used to
accelerate provision of medical assistance in Manhic¸a. Neverthe-
less, some studies have suggested the use of biomarkers in Africa
for purposes other than clinical diagnosis [45–47], whether EPO
combined with other parameters could increase the specificity of
severe malaria endpoint in epidemiological studies remains to be
explored.
In conclusion, malaria parasites can easily be detected with
present diagnostic tools but the differentiation of malaria-
attributable severe disease remains a challenge. This study suggests
that, although EPO levels increase according to malaria severity
and are higher in severe malaria than in bacteremia, the utility of
EPO to distinguish malaria-attributable severe disease in Manhic¸a
is limited due to the overlap of values between study groups and
the main role of hemoglobin in the expression of EPO.
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